Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

作者：Nicolas Penel, Binh Bui, Jacques‐Olivier Bay, Didier Cupissol, Isabelle Laure Ray-Coquard, Sophie Piperno‐Neumann, Pierre Kerbrat, Charles Fournier, Sophie Taieb, Marta Jiménez, Nicolás Isambert, Frédéric Peyrade, Christine Chevreau, Emmanuelle Bompas, Etienne G.C. Brain, Jean‐Yves Blay · 发表于：Journal of Clinical Oncology · 年份：2008 · DOI：10.1200/jco.2008.17.3146 · 被引用次数：696 · 研究领域：Vascular Tumors and Angiosarcomas、Cardiac tumors and thrombi、Cancer Treatment and Pharmacology

PURPOSE: The objective of this phase II trial was to assess the efficacy and toxicity of weekly paclitaxel for patients with metastatic or unresectable angiosarcoma. PATIENTS AND METHODS: Thirty patients were entered onto the study from April 2005 through October 2006. Paclitaxel was administered intravenously as a 60-minute infusion at a dose of 80 mg/m(2) on days 1, 8, and 15 of a 4-week cycle. The primary end point was the nonprogression rate after two cycles. RESULTS: The progression-free survival rates after 2 and 4 months were 74% and 45%, respectively. With a median follow-up of 8 months, the median time to progression was 4 months and the median overall survival was 8 months. The progression-free survival rate was similar in patients pretreated with chemotherapy and in chemotherapy-naïve patients (77% v 71%). Three patients with locally advanced breast angiosarcoma presented partial response, which enabled a secondary curative-intent surgery with complete histologic response in two cases. One toxic death occurred as a result of a thrombocytopenia episode. Six patients presented with grade 3 toxicities and one patient presented with a grade 4 toxicity. Anemia and fatigue were the most frequently reported toxicities. CONCLUSION: Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.